Pioneering the Future of Cancer Treatment: Samsung Bioepis Accelerates Development of Keytruda Biosimilar
[su_heading size=”27″ align=”left” margin=”40″]Samsung Bioepis Leads the Race in Developing World’s Top Immunotherapy Biosimilar[/su_heading] In the high-stakes world of biopharmaceuticals, Samsung Bioepis is setting the pace by intensifying its development efforts for a biosimilar of Keytruda, Merck’s (MSD) leading immunotherapy drug. This comes at a crucial time as the global market for such therapies is … Read more